​Important medicines required to support patients being treated for covid-19 and which we expect to be in increased demand will be given priority during the pandemic.

This may lead to delays in the national approval of the Norwegian product information and granting of MAs for other medicinal products.

MAHs must take into account the possibility of delays in the national phase for MA-applications that are not related to covid-19 as long as the emergency preparedness due to the coronavirus persists.

​Fant du det du lette etter?